scholarly journals The Clinicopathological Features and Staging at Presentation of Gastric Cancer: A Single-Center Retrospective Study

2020 ◽  
Vol 06 (03) ◽  
pp. 120-126
Author(s):  
Syn Yi Chong ◽  
Soo Fan Ang

Abstract Introduction Gastric cancer (GC) is the third leading cause of cancer death, with most patients diagnosed at a later stage, with distant metastasis at the time of presentation, contributing to poor prognosis. GC has been associated with nonspecific clinical presentations, which cause a time delay for patients to seek for medical advice. This study aims to identify the clinicopathological features of GC patients and correlate time delay of the diagnosis to the staging of the disease. Materials and Methods This is a single-center retrospective study of GC patients diagnosed from January 2012 to December 2018. All relevant data of GC patient diagnosed during this time period were extracted from the patients’ case notes. Results A total of 69 GC patients were included in this study, with male preponderance and mean age of 62 years old. The top three symptoms presented are dyspepsia or ingestion (47.8%), weight loss (43.5%), and nausea or vomiting (33.3%). The mean time delay was 3.7 months. Patients presented with weight loss have a significantly longer average time delay of 4.88 months. Most tumor lesion was found at the distal stomach (43.5%), while 74.5% tested negative for Helicobacter pylori. Most patients were diagnosed at Stage IV (52.6%) and Stage III (36.8%) of the disease, with poorly differentiated (67.7%) histological features which have poor prognosis. Discussion and Conclusion No evidence of specific symptom or combination of symptoms predicts higher risk of GC. Regardless of the number of symptoms presented or the time delay, most GC patients were diagnosed at later stage of the disease. The study shows the importance of GC screening in Malaysia to ensure early detection, even before a symptom presented.

2020 ◽  
Vol 46 (12) ◽  
pp. e1
Author(s):  
M.C. Vannoni ◽  
V. Bartolini ◽  
E. Marino ◽  
L. Graziosi ◽  
A. Donini

2020 ◽  
Vol 5 (3) ◽  
pp. S370
Author(s):  
G. KUMRU ◽  
Ş. Erdogmuş ◽  
Z. Kendi Çelebi ◽  
S. Aktürk ◽  
L. Akdoğan ◽  
...  

Surgery ◽  
2000 ◽  
Vol 128 (1) ◽  
pp. 41-47 ◽  
Author(s):  
Hirofumi Kubota ◽  
Tsukasa Kotoh ◽  
Reiko Masunaga ◽  
Dipok Kumar Dhar ◽  
Muneaki Shibakita ◽  
...  

Esophagus ◽  
2020 ◽  
Vol 17 (3) ◽  
pp. 270-278 ◽  
Author(s):  
Sanshiro Kawata ◽  
Yoshihiro Hiramatsu ◽  
Yuka Shirai ◽  
Kouji Watanabe ◽  
Tetsuyuki Nagafusa ◽  
...  

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 9090-9090
Author(s):  
Tejas Patil ◽  
Rao Rashid Mushtaq ◽  
Sydney Marsh ◽  
Christine Azelby ◽  
Miheer Pujara ◽  
...  

9090 Background: The clinicopathologic characteristics and optimal treatment strategies for non-sensitizing EGFR ( ns- EGFR) and HER2 activating mutations in NSCLC remain unclear. Methods: Single-center retrospective study of patients seen at University of Colorado from 2008 – 2018 with stage IV NSCLC was performed. Clinicopathologic features and treatment outcomes of patients with ns-EGFR (Exon 18, Exon 20, L861Q) and HER2 mutations were collected. Best response to TKI was determined (RECIST v1.1). PFS was calculated using Kaplan-Meier method. Results: Among 359 patients, we identified 49 ns-EGFR (36 Exon 20, 10 Exon 18, 3 L861Q) and 28 HER2 mutations (27 Exon 20, 1 gene amplification) detected via NGS (65/77), real-time PCR (9/77), FISH (1/77) and undocumented (2/77). PDL1 > 50% was seen in 44% ns- EGFR and 57% HER2. Adenocarcinoma was the most common histology (97%). Most patients were female (62%), never smokers (63%), and presented with metastatic disease (stage: I 5%, II 4%, III 6%, IV 85%). HER2+ NSCLC demonstrated a tropism for lung metastases (64%) that was significant when compared to EGFR Exon 19, EGFR L858R, ALK, ROS1, and KRAS cohorts (p < 0.001). No differences were found when other metastatic sites were compared. Among evaluable patients, response rates to TKI therapy is shown. Aggregate median PFS on TKI for ns-EGFR and HER2+ NSCLC was 6 months compared to EGFR Exon 19 (15 months; p < 0.01; HR 0.4; CI 0.24 – 0.67) and EGFR L858R (22 months; p < 0.01; HR 0.27 and 0.8; CI 0.14 – 0.54). Aggregate median OS for ns-EGFR and HER2+ NSCLC was 28 months with no differences when compared to EGFR Exon 19 and L858R subgroups. Conclusions: HER2+ NSCLC appears to have a predisposition for lung metastases. Higher DCR was observed with newer generation TKIs, but novel targeted therapeutic approaches are needed as overall outcomes remain poor. [Table: see text]


Sign in / Sign up

Export Citation Format

Share Document